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Abstract
Background: Antimicrobial peptides are components of the innate immune system. Cathelicidin LL-37 plays an important role in antimicrobial defense, 
exerts proinflammatory effect and strongly affects the immune system functioning. Our recent study revealed that serum concentration of LL-37 is increased 
in patients with bipolar disorder. Objectives: The aim of this study is to re-evaluate serum LL-37 levels in patients with euthymic bipolar disorder and in 
healthy controls, matched for anthropometric and body composition parameters. Methods: 36 adult patients with euthymic bipolar disorder and 68 non-
depressed adults were included into the study. Concentration of LL-37 in serum was assessed using ELISA method. Detailed anthropometric measurements, 
body composition and biochemical analyses were performed. Results: There was a statistically significant difference (p = 0.01) in serum LL-37 level between 
patients with bipolar disorder (4.97 ± 7.98 ng/mL) and control subjects (1.78 ± 2.69 ng/mL). Discussion: Results of this study indicate that LL-37 serum level is 
increased in euthymic bipolar disorder patients. We found that this increase could not be attributed to analyzed anthropometric or body composition parameters.
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Introduction
Bipolar disorder (BD) is a common, severe, and persistent mental 
illness. Primary symptoms of BD are recurrent episodes of depression 
that alternate with periods of an excessively elevated or irritable mood 
known as mania1. While exact lifetime prevalence of BD is not known, 
it is estimated that about 1% of the general population is affected by 
this condition, while less than half of bipolar patients receives medical 
help2. There is an increasing body of evidence that immune alterations 
play a major role in the development and course of BD, for example 
prevalence of autoimmune diseases, allergic diseases, and systemic 
inflammatory disorders is higher in BD patients3-6.
Cathelicidins are antimicrobial peptides synthesized by humans 
and animals in response to various stimuli. The only one known 
member of the cathelicidin family expressed in humans is LL-37. 
Cathelicidin LL-37 exhibits broad spectrum of antimicrobial 
activity against Gram-positive and Gram-negative bacteria, viruses, 
fungi and protozoa. Moreover, besides its antimicrobial functions, 
increasing evidence points out that cathelicidin LL-37 influences 
function of cells involved in adaptive and innate immune response 
and takes part in the regulation of physiological and pathological 
processes. Several studies also suggest that LL-37 strongly affects 
inflammatory processes7,8. This peptide can stimulate inflammatory 
cells to produce and release pro-inflammatory cytokines, mediate 
production of anti-inflammatory mediators, as well as contribute to 
host homeostasis7,9-11.
We have previously found12 that serum concentration of 
LL-37 is elevated in euthymic patients with bipolar disorder. This 
could confirm previously postulated role of inflammation in the 
development of BD6. There is however at least one other alternative 
explanation of this finding, which requires to be examined: observed 
changes in LL-37 could result from changes in body weight (and 
accumulation of body fat) that are secondary to treatment with 
mood-stabilizer. Patients treated with these medications (valproate, 
lithium, second generation antipsychotics) may gain a considerable 
amount of body weight13 and obesity is linked to increased numbers 
of immune cells, predominantly macrophages, accumulating in the 
adipose tissue, where they produce cytokines of pro-inflammatory 
character14.
Therefore, a question arises whether observed increase of LL-37 
serum concentration in BD could be attributed to treatment induced 
weight-gain and increased amount of body fat. The aim of this study 
is to find whether previously found (and confirmed in this study) 
increase of LL-37 in euthymic BD patients could be attributed to 
differences in anthropometric parameters or body.
Material and methods
Subjects
This was the extension of our original study, with new subjects (10 
patients and 16 healthy subjects) enrolled and included into the 
analysis. Thirty-six adult European Caucasian patients with bipolar 
disorder (F31 according to ICD-10) were included into the study 
(the BD group). Diagnosis was established attending psychiatrist, 
using formal ICD-10 criteria. All patients were euthymic, which 
was indicated by normal, stable mood for at least 2 months prior the 
study and on stable treatment for at least 2 months prior the study. 
Sixty-eight adult European Caucasian were selected as the control 
group. The control group was selected from a larger sample to match 
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age, gender composition, anthropometric, metabolic and body 
composition parameters of the BD group. The healthy volunteers 
had neither self-reported personal or familial psychiatric history 
nor medication history from semi-structured interview and had 
normal laboratory findings. All study subjects had a normal blood 
profile, ALT, AST, urea, creatinine, bilirubin, and electrolytes were 
in norm. Subjects with acute and chronic inflammatory conditions 
(e.g. pneumonia, rheumatoid arthritis), immunological disorders 
(e.g. AIDS, allergy), and cancer were excluded from the study. All 
patients included in the study have been informed about aims and 
methods of the study and expressed their written informed consent 
for participation in this study. The study protocol was approved by 
the Bioethics Committee of the Medical University of Łódź, Poland. 
There was no financial involvement from the industry.
Laboratory tests
Blood samples were collected between 8 am and 9 am after ensuring at 
least 8 h overnight fasting. The samples were collected directly into serum 
separator tubes and centrifuged (10 min, 3,500 rpm). Fasting plasma 
glucose and lipids (total cholesterol, HDL cholesterol, LDL cholesterol 
and triglycerides) were measured using automatic Dirui CS-400 analyzer 
(Dirui, China). Serum concentration of cathelicidin LL-37 was assessed 
using commercial ELISA kit (MyBIOSource) (the sensitivity of this assay 
was 0.938 ng/mL), according to instructions provided in the manual. 
Serum was collected and stored at -80 ºC until assayed (up to 6 months). 
All samples were compared to the standard curve.
Anthropometry
Height was measured with a wall-mounted height measure to the 
nearest 0.5 cm. Weight was measured with a seca 955 (seca, UK) 
digital chair scale that was kept on a firm horizontal surface, with 
subjects undressed. Waist and hip circumferences were measured 
using a non-stretchable fiber measuring tape. Body mass index (BMI) 
was calculated as body weight in kilogram divided by the height in 
meter squared (kg/m2). Waist-to-hip ratio (WHR) was calculated as 
waist circumference divided by hip circumference.
Body composition
Body composition was measured using two methods: bioimpedance 
analysis (BIA) and dual-energy X-ray absorptiometry (DXA). 
For BIA we used Maltron BIOSCAN 920-2-S Body Fat Analyzer 
(Maltron, UK), multi-frequency (5 kHz, 50 kHz, 100 kHz, 200 
kHz) bioelectrical impedance analyzer. For DXA we used Lunar 
iDXA scanner (GE Healthcare, UK) with latest version of CoreScan 
software. Standard operating conditions (including preparation of 
the participants, electrodes placement and measurement procedures) 
were monitored by a trained operator. The measurement using 
DXA and BIA was taken immediately prior to anthropometry 
measurements with participants lying supine, resting. Briefly, BIA 
determines the electrical impedance, or opposition to the flow of 
an electric current through body tissues which can then be used 
to calculate an estimate of total body water, which can be used to 
estimate fat-free body mass and, by difference with body weight, 
body fat. In DXA two X-ray beams, with different energy levels, are 
aimed at the patient’s body and different tissue types (bone, muscle, 
fat) can be determined from the absorption of each beam by tissues.
The following body composition parameters were measured 
using DXA method: TBF (total body fat), LBM (lean body mass), 
VAT (visceral adipose tissue) mass, VAT volume. TBF and LBM are 
expressed both in kilograms and as percentage of total body mass. 
SAT (subcutaneous adipose tissue) and VAT areas are measured 
at the level of the umbilicus, using data input from Maltron BIA 
analyzer (with special electrodes placement for these measurements) 
and Maltron software, which converts raw data (impedance and 
phase angle). 
BMI ranges were defined according to WHO recommendations 
(normal: 18.5-25 kg/m2, overweight: 25-30 kg/m2, obesity > 30 
kg/m2). Fat mass index (FMI) was calculated as total body fat in 
kilogram (measured using DXA method) divided by the height in 
meter squared (kg/m2).
Statistical analysis
Statistical procedures were performed with STATA 15.0 (StataCorp, 
USA). Simple descriptive statistics (means and standard deviations) 
were generated for all continuous variables. For discrete variables 
number of patients and percentages are given. Normality of 
distribution was tested with Shapiro-Wilk test. Variables with 
normal distribution were analyzed using two-tailed t-test or 
ANOVA, otherwise Wilcoxon rank sum and Kruskal-Wallis tests 
were used. Associations were tested by Pearson’s (for variables with 
normal distribution) or Spearman’s (for other variables) correlation 
coefficients. Linear regressions were performed to examine the 
relationship between serum LL-37 and anthropometric parameters 
and body composition. Adjusted effect sizes, P values, F values and 
R2 were computed for the linear regression models. The level of 
significance was set at p < 0.05 (two sided).
Results
Demographic and clinical characteristics are shown in Table 1. 
Detailed analysis of cardio-metabolic anthropometric and body 
composition parameters is also shown in Table 1. There were some 
inter-group differences for smoking, WHR, lipid lowering treatment, 
HDL- and LDL-cholesterol, FMI and total body fat (expressed as % 
of total body weight). Mean treatment duration of the BD patients 
was 140.4 ± 126.3 months, with mean number of hospitalizations 4.6 
± 4.3. Treatment in the study group was heterogeneous and included 
both mood stabilizers, antipsychotics and antidepressants. Detailed 
treatment for each study subject is shown in Table 2.
We have found a significant difference (z = -2.56, p = 0.01) in 
serum LL-37 level between BD patients (4.97 ± 7.98 ng/mL) and 
control subjects (1.78 ± 2.69 ng/mL). This difference remained 
significant (ANCOVA analysis, p < 0.05 for all comparisons) after 
adjusting for cardio-metabolic parameters (including smoking, 
WHR, lipid lowering treatment, HDL- and LDL-cholesterol, FMI and 
total body fat). In the BD group, but not in the control group, level 
of LL-37 was higher in women (5.92 ± 8.89 vs. 2.51 ± 4.34 ng/mL, 
p = 0.02). In both study groups there were no correlations between 
LL-37 level and age. Also, in the BD group there were no correlations 
between LL-37 level and treatment duration. Due to heterogeneity 
of pharmacological treatment, we were not able to evaluate effect of 
individual medications on LL-37 level. We have found that subjects 
taking lipid lowering medications (statins) had significantly lower 
LL-37 level (1.31 ± 0.88 vs. 3.44 ± 6.11 ng/mL, p = 0.004); no such 
differences were found for subjects treated with anti-hypertensive or 
anti-diabetic medications. Analysis of the association between serum 
LL-37 and anthropometric parameters or body composition was 
performed using linear regression. Since LL-37 levels may be affected 
by age and smoking, linear regression models were adjusted for sex, 
age and smoking. Results of regression analysis are shown in Table 3.
Discussion
This is the first study that analyzed the association between LL-37 
level and anthropometric parameters or body composition in BD 
subjects. Previously, our group found that compared with healthy 
controls, level of LL-37 is increased in patient with BD12 or unipolar 
depression15 (these studies were based on a different samples but 
used the same LL-37 methodology as in this study). In unipolar 
depression this increase might be explained by the pro-inflammatory 
effect of cytokines produced in the visceral adipose tissue. In this 
study our main objective was to find whether previously found 
(and confirmed in this study) increase of serum LL-37 in euthymic 
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BD patients could be attributed to any of anthropometric or body 
composition parameters. In order to do so, we have compared two 
groups of subjects (euthymic BD and healthy controls) controlled for 
anthropometric and body composition parameters. In these groups of 
subjects, we have confirmed that LL-37 was higher in the BD group. 
Finally, we found no associations between serum LL-37 and any of 
analyzed anthropometric or body composition parameters. Results of 
this study indicate that the differences in LL-37 serum levels could not 
be attributed to anthropometric or body composition abnormalities 
(e.g. increased body weight, abdominal obesity, increased total body 
fat), which are common in patients with BD. 
Growing body of evidence points to the significance of 
inflammation in bipolar disorder. In BD patients increased levels of 
pro-inflammatory cytokines, such as tumor necrosis factor (TNF), 
IL-1beta, IL-6 and IL-33 were observed16-19. Furthermore, BD patients 
have significantly elevated serum concentration of anti-inflammatory 
mediators, such as sTNFR118,20,21, sIL-6R21,22, IL-1Ra23,24, and IL-1016,25 
as compared with healthy controls. Likewise, in bipolar disorder 
patients level of IL-4 (known as immunoregulatory cytokine) is 
raised26. In bipolar depressed and manic patients serum concentration 
of CRP is elevated. Also, Significantly higher serum levels of CRP 
in bipolar disorder in partial remission were noted24,27-30. It should 
be emphasized that determination of immune and inflammatory 
parameters in mental disorder need to be considered in the context of 
metabolic parameters and body composition, since these parameters 
may significantly affect the immune system functions.
It is known that obesity is more prevalent in the population of 
patients with mental disorders. In addition, obesity may directly 
or indirectly change immunological parameters and is a chronic 
low-grade inflammation, in which there is a two-way interaction 
between adipokines and cytokines, the innate (macrophages, 
neutrophils, eosinophils, mast cells, NK cells, MAIT cells) and the 
Table 1. Demographic and clinical characteristics 
Bipolar 
disorder  
(n = 36)
Control (n 
= 68)
p
Age (years) 54.9 ± 13.5 57.8 ± 13.9 0.29
Men 10 (27.8%) 10 (14.7%) 0.11
Smokers 16 (44.4%) 9 (13.2%) < 0.001
Smoking (pocket-years) 13.9 ± 24.1 5.1 ± 9.7 0.06
Antihypertensive treatment 15 (41.2%) 17 (25.0%) 0.08
Lipid-lowering treatment 4 (11.1%) 23 (33.8%) 0.01
Antidiabetic treatment 3 (8.3%) 4 (5.9%) 0.63
Laboratory tests
Fasting glucose (mg/dL) 96.5 ± 22.8 92.9 ± 13.0 0.89
Total cholesterol (mg/dL) 190.1 ± 45.1 213.5 ± 
43.1
0.05
HDL cholesterol (mg/dL) 53.7 ± 15.7 50.7 ± 12.2 0.02
LDL cholesterol (mg/dL) 120.9 ± 32.2 138.6 ± 
39.3
0.04
Triglycerides (mg/dL) 114.3 ± 50.3 121.3 ± 
61.8
0.81
Anthropometric measurements
Weight (kg) 77.6 ± 16.3 73.0 ± 14.3 0.17
BMI (kg/m2) 27.1 ± 4.5 27.3 ± 4.7 0.80
BMI category
Normal
Overweight
Obesity
12 (33.3%)
13 (36.1%)
11 (30.6%)
21 (30.9%)
27 (39.7%)
20 (29.4%)
0.37
FMI (kg/m2] 9.4 ± 3.8 11.8 ± 5.2 0.02
Waist circumference (cm) 94.0 ± 11.5 89.7 ± 12.7 0.09
Hip circumference (cm) 103.3 ± 9.1 102.5 ± 9.6 0.71
WHR 0.99 ± 0.06 0.87 ± 0.07 0.01
Body composition
Total body fat (kg) 26.6 ± 10.5 31.1 ± 13.0 0.14
Total body fat (% of total body 
weight)
35.3 ± 14.9 41.7 ± 15.5 0.01
Lean body mass (kg) 46.0 ± 10.8 43.1 ± 9.3 0.29
Lean body mass (% of total body 
weight)
61.4 ± 16.2 58.8 ± 10.1 0.63
VAT area (cm2) 94.4 ± 53.9 111.5 ± 
81.3
0.51
SAT area (cm2) 97.8 ± 37.3 120.6 ± 
55.4
0.07
VAT mass (g) 1061.5 ± 864.0 1003.6 ± 
736.6
0.91
VAT mass (% of total body weight) 1.2 ± 0.7 1.3 ± 0.8 0.58
VAT volume (cm3) 1125.1 ± 915.8 1063.8 ± 
780.7
0.91
Data given as mean±standard deviation or n (%).
BMI: body mass index; FMI: fat mass index; WHR: waist to hip ratio; VAT: visceral adipose tissue; 
SAT: subcutaneous adipose tissue.
Table 2. Detailed pharmacological treatment in the bipolar disorder group
Subject nº Treatment
1 LIT 875, LAMO 300, QUE 400, TIAN 37.5
2 CLOM 150, CBZ 450
3 LIT 875, LAMO 300, QUE 400
4 AMI 600
5 VAL 1100
6 OLA 20, VAL 1800
7 QUE 350
8 QUE 350
9 CBZ 600
10 CBZ 600
11 CBZ 600
12 CBZ 600
13 QUE 325, LAMO 200
14 QUE 300, LAMO 200
15 LAMO 100, VEN 187.5, ARI 15
16 VEN 225, LAMO 200
17 SUL 100, LAMO 50
18 LAMO 100, QUE 750
19 LAMO 250, LIT 1000, ESCIT 5
20 QUE 300, LIT 1000, LAMO 250, ESCIT 5
21 QUE 100, LAMO 25
22 QUE 150
23 LAMO 200, QUE 600, SUL 50, OLA 15
24 LAMO 125, QUE 600, OLA 15
25 QUE 400, VAL 1500
26 QUE 400, VAL 1500
27 OLA 12.5, ESCIT 10
28 RIS 2, VAL 600, CLO 75
29 VAL 1500, QUE 300
30 VAL 1500, QUE 300
31 LAMO 100, MIAN 30
32 QUE 500, LAMO 300
33 QUE 500, LAMO 300
34 FLX 20, LAMO 50, QUE 100, OLA 7.5
35 SERT 150, MIRT 30, QUE 100
36 QUE 550
Mood stabilizers – LIT: lithium, CBZ: carbamazepine; VAL: valproate; LAMO: lamotrigine. 
Antidepressants – CLOM: clomipramine; MIRT: mirtazapine; FLX: fluoxetine; ESCIT: escitalopram; 
MIAN: mianserin; SERT: sertraline; TIAN: tianeptine; VEN: venlafaxine. Antipsychotics – CLO: 
clozapine; OLA: olanzapine; ZIP: ziprasidone; QUE: quetiapine; AMI: amisulpride; ARI: aripiprazole; 
RIS: risperidone; SUL: sulpiride.Doses given as: mg/day. 
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adaptive (CD4 T cells, CD8 T cells, regulatory T cells, and B cells) 
immune system and adipose tissue31. It should be emphasized that 
this chronic low-grade inflammation takes part in the development of 
obesity-related diseases (e.g. type 2 diabetes and insulin resistance)32. 
Gonzalez-Curiel et al. indicated that patients with diabetes mellitus 
type 2 have lower LL-37 gene expression33. On the other hand, other 
researchers reported increased serum LL-37 concentration in patients 
with diabetes34 and therefore changes of LL-37 production may also 
mediate these processes.
Data on the influence of body composition on LL-37 expression 
are still incomplete. There are studies showing that there is an 
association between metabolic parameters (such as BMI, waist 
circumference, WHR, blood glucose and lipids) and expression 
or concentration of cathelicidin LL-3735,36. Interestingly, defensins, 
which together with cathelicidins belong to the family of AMPs, are 
also affected by metabolic abnormalities, such as abnormal lipid 
profile37. Hoang-Yen Tran et al. have found that obese non-diabetic 
patients have higher levels of cathelicidin LL-37 compared with 
patients with normal BMI. Even in comparison with obese pre-
diabetic patients, obese non-diabetic patients had increased serum 
LL-37 concentrations35. Additionally, this group has found that LL-37 
inhibits the CD36 fat receptor and lipid accumulation in adipocytes 
and hepatocytes, leading to reduction of hepatic steatosis and fat 
mass. Therefore, likewise some adipokines (such as leptin) LL-37 may 
restrict obesity by inhibiting accumulation of lipids in the adipose 
tissue in response to increased body fat mass. It should be noted that 
this feedback mechanism in pre-diabetes or diabetes seems to be 
reduced and fails to protect from lipid accumulation in adipocytes, 
thus leading to further development of obesity. Benachour et al. noted 
that there are numerous positive correlations between expression 
of LL-37 and anthropometric parameters, such as BMI, waist 
circumference, systolic blood pressure and WHR36. In this study we 
did not replicate their finding that LL-37 correlates with BMI. One 
potential explanation for this are differences in BMI distribution, age, 
medications and life style of the study subjects. The disagreement 
with a study of Benachour et al.36, which shows that in women LL-37 
is strongly correlated with BMI and waist circumference may result 
from differences in both studies protocols. Benachour et al. measured 
LL-37 expression at the mRNA level in peripheral blood mononuclear 
cells, while we assessed serum LL-37 levels. Also, the distribution of 
obesity was different between both studies, with higher percentage 
of subjects overweight or obese in our study and higher percentage 
of patients with normal BMI in the study of Benachour et al. Lack 
of correlation between LL-37 and BMI was previously reported by 
Cakir et al. in children with tuberculosis38.
Another potential explanation for higher level of LL-37 in the 
BD group is the effect of lipid-lowering treatment. Increasing body of 
evidence indicates that statins have anti-inflammatory properties39. 
Since there were more subjects in the control group taking statins, 
this could translate into lower LL-37 concentration in this group. 
However, while there are no studies evaluating a direct effect of lipid-
lowering medications on LL-37 concertation, Huang et al. observed 
that statins enhance activity of another antimicrobial peptide (beta-
defensin 2) in Salmonella-infected intestinal epithelial cells40. These 
authors have suggested that enhanced activity of antimicrobial 
peptides by statins could protect the host against infections, while 
modulation of pro-inflammatory responses could prevent the 
detrimental effects of overwhelming inflammation in the host.
General conclusion from these limited studies is that since 
cathelicidins are associated with inflammatory conditions, one can 
expect an increase of these peptides in obesity. The mechanism 
linking obesity with altered LL-37 expression may be located in 
the adipose tissue, involved in the metabolism of endogenous sex 
steroid hormones (e.g. progesterone, which influences autoimmune 
and infectious diseases via adaptive and innate effects, also involving 
alterations of antimicrobial peptides, such as defensins and LL-37)41.
In conclusion, our study showed that in euthymic bipolar patients 
there is increased serum LL-37 level and this difference could not 
Table 3. Linear regression analysis (adjusted for sex, age and smoking) of serum LL-37 and metabolic parameters
Bipolar disorder Control
Beta p F R2 Beta p F R2
Weight (kg) 0.01 0.98 0.67 0.08 0.04 0.77 0.28 0.02
BMI (kg/m2) 0.04 0.81 0.68 0.08 0.02 0.85 0.27 0.02
FMI (kg/m2) 0.06 0.73 0.70 0.08 -0.05 0.71 0.30 0.02
Waist circumference (cm) 0.04 0.82 0.68 0.08 0.01 0.91 0.27 0.02
Hip circumference (cm) 0.08 0.67 0.72 0.08 0.13 0.30 0.54 0.03
WHR -0.03 0.88 0.68 0.08 -0.14 0.33 0.51 0.03
Total body fat (kg) 0.04 0.79 0.69 0.08 -0.04 0.77 0.29 0.02
Total body fat (%)† 0.02 0.90 0.67 0.08 -0.07 0.60 0.29 0.02
Lean body mass (kg) -0.04 0.81 0.68 0.08 0.06 0.60 0.33 0.02
Lean body mass (%)† -0.06 0.72 0.70 0.08 0.01 0.92 0.22 0.01
VAT area (cm2) 0.04 0.81 0.68 0.08 -0.09 0.47 0.32 0.02
SAT area (cm2) 0.14 0.43 0.84 0.09 -0.11 0.41 0.37 0.02
VAT area to SAT area ratio -0.08 0.68 0.71 0.08 -0.03 0.82 0.20 0.01
VAT mass (g) -0.11 0.62 0.74 0.09 0.01 0.99 0.26 0.02
VAT mass (%)† -0.11 0.62 0.74 0.09 -0.01 0.99 0.26 0.02
VAT volume (cm3) -0.11 0.62 0.74 0.09 0.01 0.99 0.26 0.02
Fasting glucose (mg/dL) -0.01 0.98 0.67 0.08 -0.01 0.98 0.26 0.02
Total cholesterol (mg/dL) -0.07 0.70 0.71 0.08 0.18 0.15 0.80 0.05
HDL cholesterol (mg/dL) 0.01 0.96 0.67 0.08 0.03 0.82 0.28 0.02
LDL cholesterol (mg/dL) 0.27 0.15 1.27 0.14 0.19 0.13 0.87 0.05
Triglycerides (mg/dL) 0.09 0.61 0.74 0.09 -0.02 0.93 0.26 0.02
Lipid-lowering treatment -0.18 0.35 0.91 0.11 -0.20 0.13 0.87 0.05
Beta: standardized regression coefficient; F: F-statistic; R2: coefficient of determination.
BMI: body mass index; FMI: fat mass index; WHR: waist to hip ratio; VAT: visceral adipose tissue; SAT: subcutaneous adipose tissue.
† Percentage of total body weight.
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attributed to any of analyzed body composition parameters. Our results 
extend the current knowledge about the role of inflammatory proteins 
in bipolar disorder. Limitations of the study include: relatively small 
study groups, heterogeneous treatment and cross-sectional design, 
which limits its ability to establish a causal relationship. Another 
potential limitation is that diagnosis was only based on clinical ICD-10 
criteria and clinical symptoms were not measured using formal 
diagnostic tools. It was previously reported that vitamin D may affect 
LL-37 concentration42. Since we have no data for vitamin D status, 
we could not control our results for this variable. On the other hand, 
we studied subjects from groups that are very comparable in terms of 
many confounding factors, thus limiting their impact on the results.
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